Small-molecule inhibitors of signaling recognize ... One target for such inhibition, the p38 mitogen-activated protein kinase (MAPK) signaling cascade, has a role in inflammation by mediating ...

Small-molecule inhibitors of mitogen-activated protein kinase (MAPK) have shown great promise as therapeutic agents in preclinical studies of inflammatory arthritis. The disappointing results of ...

Matchpoint Therapeutics Inc. has synthesized new diazepino-thieno-quinoxaline compounds acting as MAP kinase-activated protein kinase 2 (MAPKAPK2; MK2) inhibitors reported to be useful for the ...

MD Biopharm Co. Ltd. has identified compounds acting as mitogen-activated protein kinase kinase kinase 11 (MAP3K11; MLK3) and kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the ...

Clinical-stage biopharmaceutical company Poolbeg Pharma announced on Wednesday that it has been granted a US patent for its ...

Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focused on the development and commercialisation of innovative medicines targeting diseases with a ...

Today, thanks in no small part to the advent of kinase inhibitors, the disease is treated by a few pills with minimal side-effects. “Kinase inhibitors have truly revolutionised the way we treat CML,” ...

[59] The aurora kinase inhibitor MK-0457 (VX-680) and the p38 MAP kinase inhibitor BIRB-796 [60] were also reported to be effective against T315I. Since the discovery of these inhibitors ...